Florida International University (FIU) is seeking a business partner to develop and commercialize Novel Inhibitors of Bacterial Quorum Sensing (QS). These compounds have shown inhibition of the pathogenicity of Gram-negative bacteria such as Pseudomonas aeruginosa, an important human opportunistic pathogen affecting immunocompromised individuals, cancer patients, burn victims, cystic fibrosis patients, and patients with impaired lung function.
As antimicrobial resistance is a growing global threat, it is imperative to develop alternative therapeutic approaches. Quorum sensing (QS) is a type of bacterial cell-to-cell signaling pathway mediated through the production, release, and detection of the small signaling molecules called autoinducers (AIs). Such communication allows bacterial control of crucial function including virulence factors and biofilm formation. If achieved, the inhibition of QS would reduce bacterial pathogenicity, thus providing disease prevention and treatment. The most common QS signaling molecule used by Gram-negative bacteria are acylhomoserine lactones (AHLs). The development of non-native acylhomoserine lactone (AHL) ligands has emerged as a promising new strategy to inhibit QS in Gram-negative bacteria.
FIU inventors have developed new optically pure γ-lactams and cyclic azahemiacetals, bearing alkylthiomethyl substituents with different carbon chain lengths, that are capable of inhibiting bacterial QS pathways.
- Treatment and prevention of infections caused by Gram-negative bacteria in human, animals and plants
- Surface treatment of surgical instruments, medical and healthcare devices, food processing, water treatment, and agriculture equipment, boat hull, and power generating machinery and equipment
- Effective against drug resistant bacterial strains
- Attenuate infection without the creation of resistant bacteria or adverse effects
- Can be used in combination with antibiotics